News | Cardiovascular Clinical Studies | October 11, 2022

ELANA Heart Bypass Solution Shows Promising Preliminary Results in First-in-Human Trials

ELANA Heart Bypass Solution shown to be safe and feasible in humans, with all candidates free of Major Adverse Cardiovascular Events (MACE) at post-operative day 30

Results now available for the first 10 patients being treated with the ELANA open heart bypass solution as part of a SAFE-CAB trial.

October 11, 2022 — The preliminary results of the first-in-human (FIH) trials for the innovative ELANA Heart Bypass Solution have been unveiled today and look promising. 

At the 36th EACTS Annual Meeting Late Breaking Trials session, Drs. Patrick Klein, cardiothoracic surgeon the St. Antonius Hospital, Nieuwegein, The Netherlands, and Dr. Bart van Putte, principal investigator of the SAFE-CAB trial, announced that the 30-day post-operative outcomes of the open procedure showed 100% of patients to be free of Major Adverse Cardiovascular Events (MACE). In all cases there was no cardiac related mortality or myocard infarction, and no need to repeat the coronary revascularization. 

This news marks an important landmark for the ELANA (Excimer Laser Assisted Non-Occlusive Anastomosis) Heart Bypass Solution and its developer, AMT Medical. In future, this innovative medical device should help facilitate the broader use of minimally invasive bypass surgery techniques. This in turn provides an alternative to traditional, gold standard, sutured (hand-sewed) CABG (Coronary Artery Bypass Grafting) surgery. If needed, the ELANA Heart Bypass Solution can also be used for CABG procedures. 

The trial is now set to be expanded to include a further 65 patients by mid-2023. Said Drs. Klein: “Having operated together on the first 10 patients, Dr. van Putte and I concluded that the ELANA Heart Bypass Solution proved to be safe and feasible in human application. We are now ready to go to the second stage of the SAFE-CAB trial to confirm these results in a broader range of patients with a longer follow-up - including graft patency assessment by coronary angiography after one year. These results will be used to achieve a European registration for the commercial use of this solution.” 

Coordinating investigator Prof. Dr. Stephan Jacobs from the German Heart Center Berlin, Germany, believes that this trial could change the game for minimally invasive heart CABG surgery - which has traditionally been technically demanding for the surgeon. “A sutureless coronary anastomosis device like the ELANA Heart Bypass Solution could effectively facilitate minimally invasive CABG,” he said. 

“This technology already has proof of concept in brain surgery; now the objective is to gather even more clinical data from this SAFE-CAB study that demonstrate its safety and preliminary efficacy in heart surgery.” 

According to Rutger Tulleken, CEO of AMT Medical, these trial results represent positive news for both surgeons - and their patients. “The ELANA Heart Bypass Solution uses a clip to connect the donor vessel behind the site of the blockage – which is then opened, allowing blood to flow through the newly made path. This clip has a major advantage over hand suturing because this connection is reproducible, and thus requires less time and skills from the surgeon,” he said. 

Tulleken continued: “For patients, it will mean less chance of infections, internal bleeding and stroke; as well as a much shorter recovery time. Once the small incision is healed, the patient can return to living a normal life.” He concluded: “Our goal is simple; to complete these first-in-human trials – and ultimately make this technology commercially available for minimal invasive CABG procedures within several years.” 

For more information: https://amt-medical.nl/ 


Related Content

News | Heart Failure

December 2, 2022 — Westchester resident, 62-year-old Miriam Nieves, is especially grateful this Thanksgiving season ...

Home December 02, 2022
Home
News | Heart Failure

December 2, 2022 — The U.S. Senate today passed the bipartisan Cardiovascular Advances in Research and Opportunities ...

Home December 02, 2022
Home
News | Heart Failure

December 1, 2022 — Scientists at the Centro Nacional de Investigaciones Cardiovasculares (CNIC) have identified a new ...

Home December 01, 2022
Home
News | Heart Failure

November 22, 2022 — Impulse Dynamics, a global medical device company dedicated to improving the lives of people with ...

Home November 22, 2022
Home
News | Heart Failure

November 21, 2022 — Cardiovascular disease remains the leading cause of death in the United States (US) and worldwide ...

Home November 21, 2022
Home
News | Heart Failure

November 22, 2022 — Myocarditis is a complication that can occur in cancer patients treated with immune checkpoint ...

Home November 21, 2022
Home
News | Heart Failure

November 15, 2022 — Ten months after transplanting the first genetically-modified pig heart into a human patient ...

Home November 15, 2022
Home
News | Heart Failure

November 14, 2022 — When it comes to heart failure (HF), sex differencesare known to impact everything from risk factors ...

Home November 14, 2022
Home
News | Heart Failure

November 9, 2022 — Lexicon Pharmaceuticals, Inc. announced that a new analysis of results from the SOLOIST-WHF Phase 3 ...

Home November 09, 2022
Home
News | Heart Failure

November 3, 2022 — Chronic heart failure causes the cell’s powerhouses to dysfunction, in part due to overconsumption of ...

Home November 03, 2022
Home
Subscribe Now